Acknowledgments
MAY
The authors thank all participants in the study for their valuable contribution toward this study. The authors also thank Quintus Medley (principal preclinical scientist, Novartis, at the time of the study) for the contribution toward developing the study drug, Catherine Zwingelstein (Novartis Institute of Biomedical Research, Cambridge, MA, USA) for project management, and all clinical site staff for their support. Medical writing support was provided by Khi Khi Choo (Novartis Corporation, Malaysia) and Swapna Ganduri (CONEXTS, Novartis Healthcare Pvt. Ltd. Hyderabad, India), in accordance with Good Publication Practice (GPP3) guidelines.Supported by Novartis Pharma AG. The sponsor or funding organization participated in the design of the study; management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript.Data presented at Association for Research in Vision and Ophthalmology (ARVO), May 1–7, 2021, Virtual Meeting.Disclosure: 